ReviewInternational journal of antimicrobial agents2020
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
Review in International journal of antimicrobial agents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and characteristics of malaria among COVID-19 individuals: A systematic review, meta-analysis, and analysis of case reports.PLoS neglected tropical diseases · 2021Pooled it
- Evaluation of the cardiopulmonary effects of repurposed COVID-19 therapeutics in healthy rats.Scientific reports · 2026Article
- Health literacy and COVID-19 pandemic impacts among adults in rural northern Arizona.Rural and remote health · 2024Article
- Harnessing immunity: Immunomodulatory therapies in COVID-19.World journal of virology · 2024Review
- Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.Journal of pharmacological sciences · 2023Review
- Review
- Novel α-aminophosphonate derivates synthesis, theoretical calculation, Molecular docking, and in silico prediction of potential inhibition of SARS-CoV-2.Journal of molecular structure · 2023Article
- Solar Photocatalysis for the Decontamination Of Water from Emerging Pharmaceutical Pollutant Chloroquine Using Nano ZnO as the Catalyst.Water, air, and soil pollution · 2023Article
- Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19.European journal of medicinal chemistry reports · 2022Review
- Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway.Journal of medical virology · 2022Review
- Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.Journal of molecular modeling · 2022Article
- Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.The American journal of emergency medicine · 2022Review
- 'A disease like any other' traditional, complementary and alternative medicine use and perspectives in the context of COVID-19 among the Congolese community in Belgium.Journal of ethnobiology and ethnomedicine · 2022Article
- Severe Acute Respiratory Syndrome Type 2-Causing Coronavirus: Variants and Preventive Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Article
- Cross-species virus transmission and its pandemic potential.Bulletin of the National Research Centre · 2022Review
- Local Anesthetic Like Inhibition of the Cardiac NaJournal of experimental pharmacology · 2022Article
- Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure.PloS one · 2022Article
- Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.Bulletin of the National Research Centre · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus infection (COVID-19) has turned into a global catastrophe and there is an intense search for effective drug therapy. Of all the potential therapies, chloroquine and hydroxychloroquine have been the focus of tremendous public attention. Both drugs have been used in the treatment and prophylaxis of malaria. Long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders. There is convincing evidence that hydroxychloroquine has strong in vitro antiviral activity against SARS-CoV-2. A few small uncontrolled trials and several anecdotal reports have shown conflicting results of such drug therapy in COVID-19. However, the results of preliminary large-scale randomized controlled trials have failed to show any survival benefit of such drug therapy in COVID-19. Despite the lack of such evidence, hydroxychloroquine has been used as a desperate attempt for prophylaxis and treatment of COVID-19. The drug has wide-ranging drug interactions and potential cardiotoxicity. Indiscriminate unsupervised use can expose the public to serious adverse drug effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.